Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the impact of age on immune checkpoint therapy biomarkers

1 Aug 2021

Abstract excerpt

Both tumors and aging alter the immune landscape of tissues. These interactions may play an important role in tumor progression among elderly patients and may suggest considerations for patient care. We leverage large-scale genomic and clinical databases to perform comprehensive comparative analysis of molecular and cellular markers of immune checkpoint blockade (ICB) response with patient age. These analyses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34433020
DOI: 10.1016/j.celrep.2021.109599

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the impact of age on immune checkpoint therapy biomarkersPMID 34433020Read ↗

Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Aging interacts with tumor biology to produce major changes in the immune tumor microenvironmentSemantic proximity Read ↗

Age-associated differences in the cancer molecular landscapeSemantic proximity Read ↗

Pan-cancer analysis reveals molecular patterns associated with age.Semantic proximity Read ↗

Pan-cancer analysis reveals unique molecular patterns associated with ageSemantic proximity Read ↗

Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitorsSemantic proximity Read ↗

MOLECULAR LANDSCAPE OF OLD AGE MELANOMA BY SURVIVAL AND IMMUNOTHERAPY RESPONSESemantic proximity Read ↗

Aging2Cancer: an integrated resource for linking aging to tumor multi-omics data.Semantic proximity Read ↗

Comprehensive transcriptome profiling in elderly cancer patients reveals aging‐altered immune cells and immune checkpointsSemantic proximity Read ↗

An integrative analysis of the age-associated multi-omic landscape across cancers.Semantic proximity Read ↗

TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.Semantic proximity Read ↗

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade ResponseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.